The Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) is a collaboration of leading scientists from UCLA, Charles R. Drew University, Friends Research Institute, and RAND Corporation. CHIPTS' research agenda incorporates advances in HIV prevention science using combination antiretroviral therapy for those living with HIV and prophylactic antiretrovirals (ARVs) for high-risk HIV-negative individuals. Yet in key populations (e.g., young MSM of color, transgender, homeless, incarcerated, African American women), especially those with concurrent substance use and mental health disorders, barriers prevent access and adherence required to benefit from ARVs. CHIPTS will bridge these gaps with a plan to promote research, dissemination and training on treatment as prevention (TasP) in HIV-positive individuals and HIV prevention that integrates ARVs for high-risk, HIV-negative individuals (pre-exposure prophylaxis, PrEP), with emphasis on those with substance use and mental health disorders. CHIPTS has three specific aims. (1) SCIENCE: To promote novel, high impact and transformational research to eliminate barriers and to increase uptake, adherence, and persistence across the HIV prevention, care and policy continua. We study behavioral, biomedical, technological and structural approaches at individual, family, community, and policy impact levels that will stop new HIV infections, particularly in key populations. (2) NETWORKING: To sponsor meetings and provide venues for collaboration among scientists, providers, insurers, policy makers and stakeholders to accelerate uptake of high impact HIV prevention. (3) CAPACITY BUILDING: To mentor and train researchers, policy makers, providers, community leaders and staff members in health, criminal justice, social service, and administrative systems to reach HIV prevention goals for 90-90-90 by 2020. Our efforts are conducted domestically and globally. CHIPTS is comprised of five Cores. (1) Administrative Core leads CHIPTS interdisciplinary team, convenes center meetings and coordinates science, networking and capacity building agendas at local, state, national, and international levels. It ensures financial and scientific integrity, leads strategic planning and promotes a Global HIV Prevention Strategies Program. (2) Development Core invests in innovative, early stage research, supports emerging investigators and promotes dissemination events. (3) Combination Prevention Core promotes research on combination behavioral, biomedical, technological and structural interventions to reduce HIV incidence and to improve viral suppression, especially in key populations and those with substance use and mental health disorders. (4) Methods Core guides innovation and impact in measurement, statistical methods, and implementation science, focusing on factors presented by those with substance use and mental health disorders. (5) Policy Impact Core optimizes public health impact and science implementation by providing evidence on policy options to guide HIV prevention policy.

Public Health Relevance

Los Angeles has the second highest number of AIDS cases nationally and has one of the most ethnically diverse epidemics. Exciting developments in HIV prevention science have shifted the fight against new HIV infections from a lack of available effective interventions to a lack of will. The UCLA Center for HIV Identification, Prevention, and Treatment Services (CHIPTS) mobilizes world class leaders in the areas of science, networking and capacity building to lead the HIV prevention agenda both domestically and internationally.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH058107-25
Application #
10090632
Study Section
Special Emphasis Panel (ZMH1)
Program Officer
Gordon, Christopher M
Project Start
1997-09-30
Project End
2022-01-31
Budget Start
2021-02-01
Budget End
2022-01-31
Support Year
25
Fiscal Year
2021
Total Cost
Indirect Cost
Name
University of California Los Angeles
Department
Family Medicine
Type
Schools of Medicine
DUNS #
092530369
City
Los Angeles
State
CA
Country
United States
Zip Code
90095
Zhang, S X; Shoptaw, S; Reback, C J et al. (2018) Cost-effective way to reduce stimulant-abuse among gay/bisexual men and transgender women: a randomized clinical trial with a cost comparison. Public Health 154:151-160
Li, Li; Comulada, W Scott; Lan, Chiao-Wen et al. (2018) Behavioral Problems Reported by Adolescents and Parents from HIV Affected Families in China. J Child Fam Stud 27:365-373
Kojima, Noah; Klausner, Jeffrey D (2018) Fight Fire With Fire: Innovations to Address Syphilis Among Men Who Have Sex With Men. Sex Transm Dis 45:e85-e86
Swendeman, Dallas; Fehrenbacher, Anne E; Roy, Soma et al. (2018) Gender disparities in depression severity and coping among people living with HIV/AIDS in Kolkata, India. PLoS One 13:e0207055
Earnshaw, Valerie A; Bogart, Laura M; Courtney, Ingrid et al. (2018) Exploring Treatment Needs and Expectations for People Living with HIV in South Africa: A Qualitative Study. AIDS Behav 22:2543-2552
Fletcher, Jesse B; Swendeman, Dallas; Reback, Cathy J (2018) Mental Health and Substance Use Disorder Comorbidity among Methamphetamine-Using Men Who have Sex with Men. J Psychoactive Drugs 50:206-213
Rotheram-Borus, Mary Jane; Swendeman, Dallas; Rotheram-Fuller, Erin et al. (2018) Family Coaching as a delivery modality for evidence-based prevention programs. Clin Child Psychol Psychiatry 23:96-109
Reback, Cathy J; Clark, Kirsty; Holloway, Ian W et al. (2018) Health Disparities, Risk Behaviors and Healthcare Utilization Among Transgender Women in Los Angeles County: A Comparison from 1998-1999 to 2015-2016. AIDS Behav 22:2524-2533
Clark, Kirsty; Fletcher, Jesse B; Holloway, Ian W et al. (2018) Structural Inequities and Social Networks Impact Hormone Use and Misuse Among Transgender Women in Los Angeles County. Arch Sex Behav 47:953-962
Fulcher, Jennifer A; Shoptaw, Steven; Makgoeng, Solomon B et al. (2018) Brief Report: Recent Methamphetamine Use Is Associated With Increased Rectal Mucosal Inflammatory Cytokines, Regardless of HIV-1 Serostatus. J Acquir Immune Defic Syndr 78:119-123

Showing the most recent 10 out of 715 publications